Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S.

J Bone Miner Res. 2013 Oct;28(10):2049-59. doi: 10.1002/jbmr.2058. Review.

2.

The kidney and bisphosphonates.

Miller PD.

Bone. 2011 Jul;49(1):77-81. doi: 10.1016/j.bone.2010.12.024. Epub 2011 Jan 11. Review.

PMID:
21232648
3.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. Review.

PMID:
20173017
4.

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

John Camm A.

Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Review.

PMID:
20399982
5.

Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.

Miller PD, Ward P, Pfister T, Leigh C, Body JJ.

Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1125-33. Review.

PMID:
19210886
6.
7.

Renal safety of intravenous bisphosphonates in the treatment of osteoporosis.

Lewiecki EM, Miller PD.

Expert Opin Drug Saf. 2007 Nov;6(6):663-72. Review.

PMID:
17967155
8.

Ibandronate: a new oral bisphosphonate for postmenopausal osteoporosis.

Guay DR.

Consult Pharm. 2005 Dec;20(12):1036-55.

PMID:
16548678
9.

Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function.

Linnebur SA, Milchak JL.

Am J Geriatr Pharmacother. 2004 Dec;2(4):213-8.

PMID:
15903279
10.

Use of bisphosphonates in older adults: how long is long enough?

Dunn RL, Bird ML, Conway SE, Stratton MA.

Consult Pharm. 2013 Jan;28(1):39-57. doi: 10.4140/TCP.n.2013.39. Review.

PMID:
23315281
11.

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

Eriksen EF, Díez-Pérez A, Boonen S.

Bone. 2014 Jan;58:126-35. doi: 10.1016/j.bone.2013.09.023. Epub 2013 Oct 9. Review.

PMID:
24120384
12.

[Bisphosphonates treatment in patients with osteoporosis].

Rizzoli R.

Ther Umsch. 2012 Mar;69(3):173-81. doi: 10.1024/0040-5930/a000270. Review. German.

PMID:
22403110
13.

Ibandronate: new options in the treatment of osteoporosis.

Adami S, Viapiana O.

Drugs Today (Barc). 2003 Nov;39(11):877-86. Review.

PMID:
14702133
14.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
15.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
16.

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM.

Osteoporos Int. 2014 Apr;25(4):1225-35. doi: 10.1007/s00198-013-2576-2. Epub 2013 Nov 28.

17.

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD.

Kidney Int. 2008 Sep;74(5):641-8. doi: 10.1038/ki.2008.193. Epub 2008 May 28.

18.

Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.

Wysowski DK, Greene P.

Bone. 2013 Dec;57(2):423-8. doi: 10.1016/j.bone.2013.09.008. Epub 2013 Sep 21.

PMID:
24063946
19.
20.

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG.

Clin Ther. 2001 Sep;23(9):1409-21. Review.

PMID:
11589256

Supplemental Content

Support Center